Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Investment analysts at Wedbush dropped their Q1 2025 earnings per share estimates for ORIC Pharmaceuticals in a report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.52) per share for the quarter, down from their prior estimate of ($0.47). Wedbush currently has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.16) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.00) EPS and FY2027 earnings at ($2.14) EPS.

ORIC has been the subject of a number of other research reports. Wells Fargo & Company initiated coverage on ORIC Pharmaceuticals in a report on Thursday, October 31st. They set an “overweight” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of ORIC Pharmaceuticals from $19.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reiterated a “buy” rating on shares of ORIC Pharmaceuticals in a report on Monday, February 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Friday. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $18.71.

ORIC Pharmaceuticals Stock Performance

ORIC Pharmaceuticals stock opened at $7.68 on Friday. ORIC Pharmaceuticals has a 52 week low of $6.33 and a 52 week high of $16.65. The stock has a market capitalization of $545.49 million, a P/E ratio of -4.22 and a beta of 1.21. The stock has a 50-day simple moving average of $9.27 and a 200 day simple moving average of $9.49.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Alkeon Capital Management LLC increased its stake in ORIC Pharmaceuticals by 2.6% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,904,096 shares of the company’s stock valued at $40,017,000 after buying an additional 100,000 shares during the last quarter. Vanguard Group Inc. grew its position in shares of ORIC Pharmaceuticals by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 3,203,789 shares of the company’s stock valued at $25,855,000 after acquiring an additional 36,478 shares during the period. Boxer Capital Management LLC bought a new position in shares of ORIC Pharmaceuticals during the 4th quarter valued at approximately $13,982,000. NEA Management Company LLC grew its position in shares of ORIC Pharmaceuticals by 4.4% during the 4th quarter. NEA Management Company LLC now owns 1,566,081 shares of the company’s stock valued at $12,638,000 after acquiring an additional 66,081 shares during the period. Finally, Balyasny Asset Management L.P. grew its position in shares of ORIC Pharmaceuticals by 37.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,555,260 shares of the company’s stock valued at $12,551,000 after acquiring an additional 424,194 shares during the period. Institutional investors and hedge funds own 95.05% of the company’s stock.

Insider Buying and Selling at ORIC Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,286.28. Following the transaction, the chief financial officer now owns 106,764 shares of the company’s stock, valued at $884,005.92. This represents a 7.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $204,184.80. Following the completion of the sale, the chief executive officer now owns 778,648 shares in the company, valued at $6,447,205.44. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,361 shares of company stock valued at $350,749. 5.55% of the stock is currently owned by insiders.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.